Tissue factor expression is differentially modulated by cyclic mechanical strain in various human endothelial cells
Intraventricular haemorrhage in preterm infants : evidence of suppressed fibrinolysis
Factor V Leiden-like behaviour of animal plasma and its use for calibration of activated protein C-dependent assays
Manifestation of cryptic fibroblast tissue factor occurs at detergent concentrations which dissolve the plasma membrane
Fibroblasts restrict tissue factor from vesicles which form in response to low concentrations of detergent
Lupus anticoagulant and thromboembolism : evaluation of fibrinogen, natural inhibitors and molecular markers of thrombosis
Binding of calcium ions and their effect on clotting of fibrinogen Milano III, a variant with truncated Aα-chains
Activation of human prothrombin by porcine aortic endothelial cells—a potential barrier to pig to human xenotransplantation
Activated protein C resistance phenotype and genotype in patients with primary antiphospholipid syndrome
Resistance to activated protein C mimicking dysfunctional protein C : diagnostic approach
Platelet adhesion to late fibrinogen degradation products
Recurrent thrombosis due to compound heterozygosity for factor V Leiden and factor V deficiency
Is heparin the ideal anticoagulant in patients with a high plasma leukocyte elastase level?
Heparin thromboprophylaxis and circulating antithrombin III levels in patients undergoing lobectomy for lung carcinoma
Immunoreactivity of cross-linked fibrin derivatives (D-dimer) and monoclonal antibodies
Joint Meeting : British Society for Haemostasis and Thrombosis/Nordic Coagulation Group
Joint Meeting : British Society for Haemostasis and Thrombosis/Nordic Coagulation Group
Tissue factor pathway inhibitor (TFPI) and heparin
Thrombin induces ‘fast’ procoagulant activity on monocytes
Regulation of tissue factor in monocytoid cell lines
Tissue factor pathway inhibitor in human endothelial cells. Internal storage pool and agonist-induced acute release
Detection of two chain factor VIIa in plasma with a novel immunoassay
Age-related increases in factor VII proteolysis and tissue factor pathway inhibitor
The protein C anticoagulant system
Identification of 19 protein S gene mutations in patients with phenotypic protein S deficiency and thrombosis
Search for mutations in the genes for FV and FVIII with a possible predisposition to APC resistance
Factor VIII resistance to activated protein C seems not to be frequent in thrombophilia
Human and bovine factor V as cofactors to activated protein C in degradation of factor VIIIa
Antiplatelet agents—biological and clinical aspects
Analysis of mutations within the GP IIb and GP IIIa genes by PCR-SSCP
A role for vitronectin in platelet aggregation by Streptococcus sanguis
Flow cytometric detection of altered platelet function : effects of age and arterial disease
Platelets activated by ADP or collagen provide coagulant phospholipids and factor V but not factor Va
Endothelial damage and adhesion molecules ICAM, VCAM and E-selectin in acute stroke
Factor VII : C levels and FVII gene polymorphisms in acute stroke
Haemostatic markers in unstable angina : a case control study
A pilot study of haemostatic, platelet and monocyte activation in heart transplant recipients
Potentially pathogenic anti-vascular endothelial cell antibodies in primary antiphospholipid syndrome (APS), SLE and scleroderma : differences in binding to umbilical vein and microvascular endothelial cells
Mechanism of action of LMW heparin
Low molecular weight heparin for prophylaxis of DVT
Low molecular weight heparin for the treatment of venous thromboembolism
LMW heparin—some unanswered questions
Molecular mobility of serpins : antithrombin and heparin
Physiological inhibitors of fibrinolysis
The serpins ovalbumin and antithrombin are stimulators of tissue plasminogen activator (tPA) enzyme activity
Kinetics of reciprocal zymogen activation in mixtures of pro-urokinase and lys-plasminogen
Lysis of Chandler model thrombi is inhibited by both plasminogen activator inhibitor and α2-antiplasmin
Vascular smooth muscle cells potentiate cell surface plasminogen activation by both uPA and tPA-dependent mechanisms
Interaction of heparin with fibrinogen and some of its derivatives
Relative benefits and risks of new antithrombotic agents
Low molecular weight heparin : the influence on lipids in patients on chronic haemodialysis
The clinical use of low molecular weight heparin (LMWH) in the refractory thromboses of malignancy associated with laboratory resolution of thrombin and factor Xa generation
Arterial thrombus formation and impaired downstream tissue perfusion : a new model in rats
Inactivated FVIIa compared with LMWH in an experimental bleeding model
Treatment of patients with FVIII inhibitors
Recombinant VIIa for bleeding in acquired haemophilia
Developing a shear stress model system to assess potential efficacy of blood products used for treatment of von Willebrand's disease
The functional activity of endothelial derived von Willebrand factor compared with plasma vWf
P1. Diagnosis of APC resistance during pregnancy
P2. Protein C activation during thromboplastin infusion in rats
P3. Development of an ARMS procedure for the factor V Leiden mutation
P4. Activated protein C resistance assays using factor V deficient plasma : the effect of instrumentation
P5. Complete discrimination for FV Q506 in plasma from OAC-patients, heparin patients and non-treated individuals using the COATEST® APCTM resistance assay after predilution in V-DEF plasma
P6. Modified COATEST® APCTM resistance assay including V-DEF plasma with a heparin antagonist : analysis of heparin and OAC plasmas and influence of preanalytical variables
P7. Effects of protein C on activation kinetics of the extrinsic pathway : mathematical modelling
P8. Precise and unbiased estimation of FV-Leiden gene frequency in a Danish birth cohort
P9. Increased resistance to activated protein C in patients with a history of arterial thrombosis
P10. Importance of Arginine1545 in factor V for activation by factor Xa
P11. Comparison of the inhibitory effects of TFPI and apolipoprotein B-100 on the procoagulant activity of thromboplastin
P12. TFPI-independent modulation of thromboplastin activity by LDL—the effects of oxidation
P13. Depletion of intravascular pools of tissue factor pathway inhibitor (TFPI) during repeated or continuous intravenous infusion of heparin in man
P14. Monocyte procoagulant activity during cardiac surgery using cardiopulmonary bypass (CPB)
P15. The effect of melatonin on cellular activation processes in human blood
P16. Modulation of blood cell activation parameters by four commonly used anticoagulants
P17. Effects of Pluronic® F-68 on platelet aggregation in human whole blood
P18. Effects of antianginal drugs on platelet function
P19. Fibrinogen β gene—455 G/A polymorphism and fibrinogen levels as risk factors for coronary artery disease in subjects with non-insulin dependent diabetes mellitus
P20. Activated factor XII and cerebrovascular disease : a novel risk factor for post-stroke mortality
P21. Influence of hormonal contraception on protein C, S and plasminogen activator inhibitor
P22. Paraoxonase Gln-Arg 192 polymorphism in subjects with ischaemic heart disease
P23. Postprandial increase in factor VIIa is related to triglyceride but not to factor XIIa or tissue factor pathway inhibitor
P24. Fibrinogen as a risk factor for coronary heart disease in the Scottish Heart Health Study
P25. Clinical reliability of the PT-derived fibrinogen assay
P26. Comparison of associations of prothrombin fragment F1.2 and D-dimer in a healthy population
P27. Red blood cells from normal and haemoglobinopathy patients deplete heparin cofactor II from plasma
P28. Experiences from outpatient treatment of deep vein thrombosis with low molecular weight heparin
P29. Pharmacokinetic study of Fragmin during the third trimester of pregnancy
P30. Concern regarding therapeutic APTT ranges : an uncertain past and an unclear future
P31. Long-term use of the low molecular weight heparin tinzaparin in haemodialysis
P32. Economic evaluation of the use of tinzaparin (Innohep®) in the treatment of deep vein thrombosis
P33. Thromboprophylaxis with Fragmin during pregnancy
P34. Heparin enhances the catalytic activity of des-ETW-thrombin
P35. Impact of random variation of international normalized ratio in monitoring oral anticoagulant therapy
P36. System ISI calibration. How many calibrant plasmas are required?
P36a. On calibration of tissue factor induced coagulation time assays
P37. Phospholipid antibodies may affect coagulation assays for factor XII
P38. The cephalin/soybean aPTT ratio. A simple means to confirming lupus anticoagulant
P39. Factor VII : C levels are elevated and related to the metabolic syndrome in first-degree relatives of patients with non-insulin-dependent diabetes
P40. Interrelationships between fibrinogen, vWF and lipid vascular risk factors in 2000 subjects with insulin-dependent diabetes mellitus (IDDM) : the Eurodiab study
P41. Platelet count and thromboembolic complications in patients operated for abdominal aortic aneurysm
P42. Enhanced tissue factor levels on circulating monocytes after heart surgery with cardiopulmonary bypass
P43. Platelet activation in unstable angina : a case control study
P44. Percutaneous transluminal angioplasty alters collagen metabolism : possible role of procollagen type-III N-terminal propeptide (PIIINP) as marker of angioplasty failure
P45. Comparison of two automated whole-blood coagulometers for assessment of clotting times during coronary bypass surgery
P46. Is heparin treatment beneficial for non-thrombolyzed patients with acute myocardial infarction?
P47. Prevention of late-occurring deep venous thrombosis with graded compression stockings
P48. PAI-1 : a risk factor in percutaneous transluminal angioplasty
P49. Antithrombin III activity is correlated with albumin in normal pregnancy
P50. Activation of the coagulation system in childhood haemolytic uraemic syndrome (HUS)
P51. Characterization of the epitope recognized by an antibody with specificity to human fibrin
P52. Fibrinolysis in overweight postmenopausal women—effect of dieting and exercise
P53. Characterization of plasminogen activator inhibitor 2 (PAI-2) in monocytes and other cell types
P54. D-dimers are degraded by human neutrophil elastase
P55. Plasminogen activator inhibitor-1 : characterization of a low molecular weight inhibitor
P56. Assessment of the in vivo anti-coagulant and anti-thrombotic activity of the thrombin inhibitor inogatran in rat and rabbit
P57. Comparison of active site blocked factors IXa and Xa in a combined rabbit model of venous stasis thrombosis and bleeding time
P58. In vivo measurement of arterial thrombus formation in rats
P59. Anion-binding exosite-directed thrombin inhibitor a synthetic analogue of thymosin α1 24–28
P60. Human prothrombin activation in an in vitro model of the pig to human xenograft reaction
P61. The structure and anticoagulant activity of a new dermatan sulphate
P62. Local application of inactivated FVIIa significantly reduces thrombus weight and improves patency in an experimental venous thrombosis model
P63. The effect of escalating dosages of active site inhibited factor VII (FVIIai) and the effect of simultaneous administration of FFR-FVIIa (FFR) and heparin on bleeding in rabbits
P64. Evaluation of a modified nail cuticle bleeding model in rabbits and of the effect of active site inhibited factor VII (FVIIai) and heparin on bleeding in this model
P65. Thrombolytic and antithrombotic effects of Paeonia anomala in low concentration
P66. Control of haemostasis using recombinant factor VIIa (rFVIIa) in liver biopsy in a patient with a bleeding tendency due to a prothrombin inhibiting lupus anticoagulant
P67. Successful control of haemostasis after emergency thoracotomy by recombinant human factor VII (rFVIIa) in a patient with haemophilia A and high titre inhibitors
P68. Moderate severity haemophilia A complicated by inhibitors
P69. Porcine factor VIII by continuous infusion in patients with haemophilia A and inhibitors
P70. Quantification of factor VIII expression in murine tissues by competitive RT-PCR
P71. Activated factor XI and potential thrombogenicity in a factor XI concentrate
P72. Assessment of batch-to-batch variation in vWF content during routine manufacture of a factor VIII concentrate, 8Y
P73. A decade of experience with a factor XI concentrate
P74. Comparison of the effects of coagulation factor concentrates on two in vitro assays of immune modulation
P75. One-stage/two-stage discrepancies in assays of FVIII concentrates—a possible role of solvent/detergent
P76. Haemocompatibility of four polyurethanes varying in hydrophobicity
P77. The haemostatic effect of alginate wound dressings
P78. Endothelial activation and inflammatory markers following bone marrow transplantation
P79. Increased levels of soluble P-selectin and von Willebrand factor in cancer : influence of radiotherapy and surgery
P80. Antioxidant supplements protect against endothelial damage in HIV infection
P81. Thrombin signal transduction pathways in endothelium
P82. von Willebrand factor (vWf) in oncologic patients
P83. ‘The von Willebrand syndrome’ in the pregnancy complicated by pre-eclampsia
Appendix 1. Modern problems of DIC